ELSEVIER

Toxicology 144 (2000) 243–245

TOXICOLOGY

www.elsevier.com/locate/toxicol

# Contents of volume 144

**Special Issue**

**FESTSCHRIFT DEDICATED TO PROFESSOR DR. K.J. NETTER**

**Guest Editor:**
**Edmund Maser**

**Laudatio**

In honour of the past European editor: K.J. Netter
W. Legrum (Germany) . . . . . 1–4

**Articles**

Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus
E.S. Vesell, K.H. Beyer, Jr. (USA) . . . . . 5–11
**Pyrazinolguanidine reduces elevated glucose, lipids and blood pressure in type 2 diabetes patients**

Use of suppression-PCR subtractive hybridisation to identify genes that demonstrate altered expression in male rat and guinea pig livers following exposure to Wy-14,643, a peroxisome proliferator and non-genotoxic hepatocarcinogen
J.C. Rockett, K.E. Swales, D.J. Esdaile, G.G. Gibson (UK) . . . . . 13–29
**Differential gene display identifies genes up- and down- regulated by a peroxisome proliferator**

Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1
H. Doostdar, M.D. Burke, R.T. Mayer (USA, UK) . . . . . 31–38
**Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A**

Estimation of human exposure to styrene and ethylbenzene
W. Tang, I. Hemm, G. Eisenbrand (Germany) . . . . . 39–50
**Exposure of the consumer (non-smoking) to styrene and ethylbenzene results to >90% from inhaled air**

Density-dependent growth of normal and nodular hepatocytes
K.W. Bock, H. Gschaidmeier, B.S. Bock-Hennig, L.C. Eriksson (Germany, Sweden) . . . . . 51–56
**Nodular hepatocytes do not show cell contact inhibition**

Effect of selenium supplementation on the activities of glutathione metabolizing enzymes in human hepatoma Hep G2 cell line
M.H. Helmy, S.S. Ismail, H. Fayed, E.A. El-Bassiouni (Egypt) . . . . . 57–61
**Selenium may protect against oxidative stress in tissue culture**

Heterogeneity of 11β-hydroxysteroid dehydrogenase type 1/microsomal carbonyl reductase (11β-HSD/CR) in guinea pig tissues. Purification of the liver form suggests modification in the cosubstrate binding site
U.C.T. Oppermann, E. Möbus, G. Nagel, E. Maser (Sweden, Germany) . . . . . 63–69
**Isoforms of 11beta-HSD in guinea pig tissues**

Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions
U.C.T. Oppermann, E. Maser (Sweden, Germany) . . . . . 71–81
**Involvement of dehydrogenases/reductases in phase I metabolism**

Use of precision-cut tissue slices in organ culture to study metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by hamster lung, liver and kidney
E. Richter, S. Friesenegger, J. Engl, A.R. Tricker (Germany, Switzerland) . . . . . 83–91
**No correlations between target organ carcinogenicity and metabolic activation of NNK in hamster tissues**

Induction of cytochrome P450 2B1-mRNA and pentoxyresorufin O-dependentylation after exposure of precision-cut rat liver slices to phenobarbital
D. Müller, P. Steinmetzer, K. Pissowotzki, R. Glöckner (Germany) . . . . . 93–97
**In vitro exposure of liver slices to phenobarbital induces CYP2B1-mRNA tremendously**

Effects of cotinine at cholinergic nicotinic receptors of the sympathetic superior cervical ganglion of the mouse
K.-C. Schroff, P. Lovich, O. Schmitz, S. Aschhoff, E. Richter, J. Remien (Germany). . . . . 99–105
**Cotinine has antagonistic action at peripheral neuronal nicotinic receptors**

Environmental inhibition of 11β-hydroxysteroid dehydrogenase
M.M. Reidenberg (USA) . . . . . 107–111
**Dietary and other exogeneous inhibitors of 11ßHSD may influence electrolyte metabolism**

Human 11β-hydroxysteroid dehydrogenase 1/carbonyl reductase: recombinant expression in the yeast *Pichia pastoris* and *Escherichia coli*
A. Blum, H.-J. Martin, E. Maser (Germany) . . . . . 113–120
**Recombinant 11ß-HSD1 serves as a valuable tool in studies on carbonyl compound detoxification**

Toxicologic evidence of developmental neurotoxicity of environmental chemicals
H.R. Andersen, J.B. Nielsen, P. Grandjean (Denmark) . . . . . 121–127
**Basic kinetic data are lacking in risk assessment of developmental neurotoxicants**

Genetic polymorphism of CYP2A6 in the German population
M. Bourian, H. Gullstén, W. Legrum (Germany, Finland) . . . . . 129–137
**Genetic polymorphism of CYP2A6**

CYP2A6: a human coumarin 7-hydroxylase
O. Pelkonen, A. Rautio, H. Raunio, M. Pasanen (Finland). . . . . 139–147
**Substrates, inhibitors and modifying factors of human CYP2A6 are described**

Laryngeal mucosa of head and neck cancer patients shows increased DNA damage as detected by single cell microgel electrophoresis
P. Schmezer, T. Rupprecht, M. Tisch, H. Maier, H. Bartsch (Germany) . . . . . 149–154
**Head and neck cancer patients show increased DNA damage in their laryngal mucosa**

Confounding variables in the environmental toxicology of arsenic
T. Gebel (Germany). . . . . 155–162
**Se, Sb, Zn, cellular resistance and genetic polymorphisms may modulate the long-term toxicity of As**

Lack of quinone reductase activity suggests that amyloid-β peptide/ERAB induced lipid peroxidation is not directly related to production of reactive oxygen species by redoxcycling
S. Salim, C. Filling, E. Mårtensson, U.C.T. Oppermann (Sweden). . . . . 163–168
**Oxidative stress by amyloid beta peptide/enzyme interactions**

Dose and time as variables of toxicity
K.K. Rozman, J. Doull (USA, Germany) . . . . . 169–178
**Development of a theory of toxicology**

Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse
E.A. Lock, P. Gaskin, M.K. Ellis, W. McLean Provan, M. Robinson, L.L. Smith (UK). . . . . 179–187
**Inhibition of mouse liver HPPD causes tyrosinaemia, but not corneal injury**

Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro
T. Iffert, M. Soldan, A. Moeller, E. Maser (Germany) . . . . . 189–195
**Liposomal encapsulation did not increase DRC toxicity**

Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles
D.F.V. Lewis (UK) . . . . . 197–203
**QSARs in human cytochromes P450**

Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs
P.N. Kourounakis, K. Tsiakitzis, A.P. Kourounakis, D. Galanakis (Greece) . . . . . 205–210
**Antioxidant NSAID derivatives with greatly reduced ulcerogenicity**

Enhanced expression of CYP1B1 in *Escherichia coli*
I. Jansson, I. Stoilov, M. Sarfarazi, J.B. Schenkman (USA). . . . . 211–219
**Human cytochrome P450 expression in Escherichia coli**

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol
A. Aigner, S.S. Hsieh, C. Malerczyk, F. Czubayko (Germany, USA) . . . . . 221–228
**Taxol cytotoxicity related to HER-2 expression level**
Monitoring of cytochrome P-450 1A activity by determination of the urinary pattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats
U. Jorritsma, E. Schrader, G. Klaunick, J. Kapitulnik, K.I. Hirsch-Ernst, G.F. Kahl, H. Foth (Germany, Israel) . . . . . 229–236
**The caffeine metabolite pattern was used to assess CYP1A induction**

**Author index of volume 144** . . . . . 237
**Subject index of volume 144** . . . . . 239–241
**Contents of volume 144** . . . . . 243–245